{"id":"loxo-305","safety":{"commonSideEffects":[{"rate":"34%","effect":"Neutropenia"},{"rate":"24%","effect":"Thrombocytopenia"},{"rate":"21%","effect":"Anemia"},{"rate":"20%","effect":"Fatigue"},{"rate":"18%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"LOXO-305 is a selective inhibitor of Bruton's tyrosine kinase (BTK), a key component of the B-cell receptor signaling complex. Inhibition of BTK has been shown to be effective in treating certain types of non-Hodgkin lymphoma.","oneSentence":"Selective Bruton's tyrosine kinase (BTK) inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:38:37.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory mantle cell lymphoma"},{"name":"Relapsed or refractory marginal zone lymphoma"}]},"trialDetails":[{"nctId":"NCT05529069","phase":"PHASE2","title":"Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-01-25","conditions":"Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy","enrollment":30},{"nctId":"NCT05254743","phase":"PHASE3","title":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2022-07-22","conditions":"Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell","enrollment":662},{"nctId":"NCT05024045","phase":"PHASE1","title":"Study of Oral LOXO-338 in Patients With Advanced Blood Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-09-30","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin","enrollment":316},{"nctId":"NCT06876662","phase":"PHASE4","title":"A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-20","conditions":"Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma","enrollment":279},{"nctId":"NCT06876649","phase":"PHASE4","title":"A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-20","conditions":"Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma","enrollment":787},{"nctId":"NCT05990465","phase":"PHASE1","title":"LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-02-06","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma","enrollment":12},{"nctId":"NCT06466122","phase":"PHASE2","title":"Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi","status":"RECRUITING","sponsor":"Kerry Rogers","startDate":"2024-11-07","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":30},{"nctId":"NCT05677919","phase":"PHASE2","title":"Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":72},{"nctId":"NCT04849416","phase":"PHASE2","title":"A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-05-14","conditions":"Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell","enrollment":87},{"nctId":"NCT04965493","phase":"PHASE3","title":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-09-20","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":600},{"nctId":"NCT03740529","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2019-03-15","conditions":"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma","enrollment":803},{"nctId":"NCT05023980","phase":"PHASE3","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-09-23","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":309},{"nctId":"NCT07162181","phase":"PHASE2","title":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-08-07","conditions":"Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma","enrollment":13},{"nctId":"NCT05317936","phase":"PHASE1, PHASE2","title":"Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-11-16","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":3},{"nctId":"NCT06390956","phase":"PHASE2","title":"Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-02-20","conditions":"Marginal Zone Lymphoma","enrollment":23},{"nctId":"NCT06948786","phase":"PHASE2","title":"Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":22},{"nctId":"NCT07220187","phase":"PHASE3","title":"Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-05-02","conditions":"Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":102},{"nctId":"NCT06252675","phase":"PHASE2","title":"Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-06-11","conditions":"Mantle Cell Lymphoma","enrollment":30},{"nctId":"NCT07122609","phase":"PHASE2","title":"Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-05","conditions":"Relapsed and Refractory DLBCL","enrollment":22},{"nctId":"NCT04662255","phase":"PHASE3","title":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-04-08","conditions":"Lymphoma, Mantle-Cell","enrollment":500},{"nctId":"NCT05734495","phase":"PHASE2","title":"Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-05-02","conditions":"Waldenstrom Macroglobulinemia","enrollment":42},{"nctId":"NCT04666038","phase":"PHASE3","title":"Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-03-09","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":238},{"nctId":"NCT06165146","phase":"PHASE1","title":"A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-10","conditions":"Healthy","enrollment":16},{"nctId":"NCT06215430","phase":"PHASE1","title":"A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-01-11","conditions":"Healthy","enrollment":16},{"nctId":"NCT04477291","phase":"PHASE1","title":"A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS","status":"TERMINATED","sponsor":"Aptose Biosciences Inc.","startDate":"2020-10-06","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":45},{"nctId":"NCT06180980","phase":"PHASE1","title":"A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-01-04","conditions":"Healthy","enrollment":20},{"nctId":"NCT06215521","phase":"PHASE1","title":"A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-12-15","conditions":"Healthy","enrollment":31},{"nctId":"NCT06180967","phase":"PHASE1","title":"A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-09-03","conditions":"Healthy","enrollment":15},{"nctId":"NCT06194214","phase":"PHASE1","title":"A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-03-11","conditions":"Healthy","enrollment":16},{"nctId":"NCT06181006","phase":"PHASE1","title":"A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-14","conditions":"Healthy","enrollment":24},{"nctId":"NCT06258174","phase":"PHASE1","title":"A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-09-28","conditions":"Healthy","enrollment":28},{"nctId":"NCT06180954","phase":"PHASE1","title":"A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-09-23","conditions":"Healthy","enrollment":9},{"nctId":"NCT06190678","phase":"PHASE1","title":"Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-01","conditions":"Healthy, Renal Insufficiency","enrollment":16},{"nctId":"NCT05134350","phase":"PHASE1","title":"Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2020-02-06","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT06190691","phase":"PHASE1","title":"Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-12-18","conditions":"Healthy, Hepatic Insufficiency","enrollment":36},{"nctId":"NCT05134337","phase":"PHASE1","title":"Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2020-02-12","conditions":"Healthy Volunteers","enrollment":27},{"nctId":"NCT05172700","phase":"","title":"Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer","status":"APPROVED_FOR_MARKETING","sponsor":"Loxo Oncology, Inc.","startDate":"","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small, Lymphoma, Mantle-Cell","enrollment":""},{"nctId":"NCT06104683","phase":"PHASE2","title":"A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis","status":"WITHDRAWN","sponsor":"Loxo Oncology, Inc.","startDate":"2024-05-01","conditions":"Relapsing Multiple Sclerosis, Multiple Sclerosis","enrollment":""},{"nctId":"NCT05833763","phase":"PHASE2","title":"A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.","status":"RECRUITING","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2023-10-12","conditions":"Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory","enrollment":42}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"FALL"},{"count":1,"reaction":"HAEMATOCHEZIA"},{"count":1,"reaction":"HYPERTENSION"},{"count":1,"reaction":"HYPERTENSIVE URGENCY"},{"count":1,"reaction":"INFUSION RELATED REACTION"},{"count":1,"reaction":"SMALL INTESTINAL OBSTRUCTION"},{"count":1,"reaction":"SUBDURAL HAEMATOMA"}],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY3527727","Pirtobrutinib"],"phase":"phase_2","status":"active","brandName":"LOXO-305","genericName":"LOXO-305","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Selective Bruton's tyrosine kinase (BTK) inhibitor Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}